A sensor may include a prism having a first face; a metal first layer covering, via a contact face, the first face; a light source; and a matrix-array detector; the device may include a dielectric second layer on which rests a transistor including a sheet made of a two-dimensional material, intended to form a channel region, a front face of the sheet comprising a specific functionalization via which specific targets are liable to be adsorbed, the specific functionalization being suitable for placing the adsorbed specific targets at a smaller distance Dd below which detection via electrical measurement by means of the specific transistor and via measurement of resonance of surface plasmons is possible.

This invention provides a method that enables determining the fibrinogen concentration in plasma of a sample. The method comprises: computing the fibrinogen concentration in whole blood of the sample using magnetic particles; computing the waveform-based hematocrit value based on the peak value of the movement signal of the magnetic particles; subjecting the fibrinogen concentration in whole blood to hematocrit correction using the waveform-based hematocrit value; and computing the fibrinogen concentration in plasma of the sample.

A method for diagnosing a malignant proliferative disease or disorder in a subject, and/or for following up, monitoring or prognosticating the therapy of a malignant proliferative disease or disorder in a subject is disclosed. The method is based on measurement of platelet-mediated fibrinogen-like protein 2 (FGL2) activity in a sample essentially comprising platelets obtained from the subject. In accordance with the disclosed method, platelet-mediated FGL2 activity level higher than control is indicative of the presence of a malignant proliferative disease or disorder in a subject.

The present invention is a method for detecting a specific disease based on the result of a measurement in which the amount of a peptide serving as a biomarker contained in a biological sample is determined by using an LC-MS. A pretreatment process performed before the measurement using the LC-MS includes the steps of preparing a mixed sample solution by adding a stable isotope reagent and a trifluoroacetic acid to the biological sample, where the stable isotope reagent is prepared beforehand by labeling the peptide with a stable isotope; boiling the mixed sample solution; injecting the mixed sample solution after boiled into a solid-phase extraction column to make the peptide be retained in the solid-phase extraction column; and passing a water-soluble organic solvent through the solid-phase extraction column to elute the peptide retained in the solid-phase extraction column and collect the eluate.

The present invention relates to a marker composition for diagnosing major depressive disorder, comprising ZA2G and prothrombin as markers, a method for providing information necessary to determine the occurrence of major depressive disorder using the marker composition, a composition for determining the occurrence of major depressive disorder, comprising agents for measurement of the expression levels of the markers, and a kit for determining the occurrence of major depressive disorder, comprising devices for measurement of the expression levels of the markers. The method for providing information for use in determining the occurrence of major depressive disorder provided by the present invention can be widely utilized to determine the occurrence of various mental disorders, including major depressive disorder since it is possible to measure the expression levels of proteins of which the expression levels are changed at the time of the occurrence of major depressive disorder, and to more objectively and accurately determine the occurrence of major depressive disorder when the method is used.

A method for diagnosing a malignant proliferative disease or disorder in a subject, and/or for following up, monitoring or prognosticating the therapy of a malignant proliferative disease or disorder in a subject is disclosed. The method is based on measurement of platelet-mediated fibrinogen-like protein 2 (FGL2) activity in a sample essentially comprising platelets obtained from the subject. In accordance with the disclosed method, platelet-mediated FGL2 activity level higher than control is indicative of the presence of a malignant proliferative disease or disorder in a subject.

Compositions including photoreactive and cleavable probes and methods of using the probes. The probes may include a tag conjugatable to a label, a cleavable linker linkable to a bait molecule, and a light activated warhead. The compositions and methods may be useful for analyzing biomolecules.

Disclosed is a reagent for prothrombin time measurement, containing a tissue factor and a surfactant, wherein the value of formula (I), which is represented by (surfactant amount (μmol))/(total protein amount (μg)), is 0.013 to 0.05 μmol/μg.

Disclosed is a reagent for prothrombin time measurement, wherein the reagent contains a liposome composition containing a first liposome having a phospholipid layer, a second liposome having a phospholipid layer of a different composition from that of the first liposome, and tissue factor, wherein the tissue factor is associated with the phospholipid layer of at least one of the first liposome and the second liposome; the first liposome contains a phosphatidylcholine compound, a phosphatidylethanolamine compound, and a phosphatidylserine compound; and the second liposome contains at least one phospholipid selected from the group consisting of a phosphatidylcholine compound and a phosphatidylethanolamine compound.

A method for measuring TAT complexes in a sample separated from a living body includes measuring TAT by performing latex immunoagglutination reaction under a condition of pH 5.8 to 6.6 using a TAT assay reagent. The TAT assay reagent includes a first antibody bound to a first latex particle, which binds to the antithrombin part of the TAT complex and recognizes the complex, and a second antibody bound to a second latex particle, which binds to the thrombin part of the TAT complex and recognizes the complex.